225 related articles for article (PubMed ID: 16280056)
21. Chromosome 7 aneusomy in metaplastic breast carcinomas with chondroid, squamous, and spindle-cell differentiation.
Gwin K; Lezon-Geyda K; Harris L; Tavassoli FA
Int J Surg Pathol; 2011 Feb; 19(1):20-5. PubMed ID: 19411277
[TBL] [Abstract][Full Text] [Related]
22. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study.
Ooi A; Takehana T; Li X; Suzuki S; Kunitomo K; Iino H; Fujii H; Takeda Y; Dobashi Y
Mod Pathol; 2004 Aug; 17(8):895-904. PubMed ID: 15143334
[TBL] [Abstract][Full Text] [Related]
23. Emerging technologies for assessing HER2 amplification.
Penault-Llorca F; Bilous M; Dowsett M; Hanna W; Osamura RY; Rüschoff J; van de Vijver M
Am J Clin Pathol; 2009 Oct; 132(4):539-48. PubMed ID: 19762531
[TBL] [Abstract][Full Text] [Related]
24. Metaplastic breast carcinoma: pathology and clinical outcome.
Bellino R; Arisio R; D'Addato F; Attini R; Durando A; Danese S; Bertone E; Grio R; Massobrio M
Anticancer Res; 2003; 23(1B):669-73. PubMed ID: 12680165
[TBL] [Abstract][Full Text] [Related]
25. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
[TBL] [Abstract][Full Text] [Related]
26. Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer.
Varga Z; Zhao J; Ohlschlegel C; Odermatt B; Heitz PU
Histopathology; 2004 Apr; 44(4):332-8. PubMed ID: 15049898
[TBL] [Abstract][Full Text] [Related]
27. Metaplastic breast carcinomas are basal-like tumours.
Reis-Filho JS; Milanezi F; Steele D; Savage K; Simpson PT; Nesland JM; Pereira EM; Lakhani SR; Schmitt FC
Histopathology; 2006 Jul; 49(1):10-21. PubMed ID: 16842242
[TBL] [Abstract][Full Text] [Related]
28. EGFR expression and activation are common in HER2 positive and triple-negative breast tumours.
Koletsa T; Kotoula V; Karayannopoulou G; Nenopoulou E; Karkavelas G; Papadimitriou CS; Kostopoulos I
Histol Histopathol; 2010 Sep; 25(9):1171-9. PubMed ID: 20607659
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma.
Tsuda H; Sasano H; Akiyama F; Kurosumi M; Hasegawa T; Osamura RY; Sakamoto G
Pathol Int; 2002 Feb; 52(2):126-34. PubMed ID: 11940217
[TBL] [Abstract][Full Text] [Related]
30. Herceptest: HER2 expression and gene amplification in non-small cell lung cancer.
Cox G; Vyberg M; Melgaard B; Askaa J; Oster A; O'Byrne KJ
Int J Cancer; 2001 May; 92(4):480-3. PubMed ID: 11304680
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy.
Marquez A; Wu R; Zhao J; Tao J; Shi Z
Diagn Mol Pathol; 2004 Mar; 13(1):1-8. PubMed ID: 15163002
[TBL] [Abstract][Full Text] [Related]
32. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections?
Sumiyoshi K; Shibayama Y; Akashi S; Nohara T; Iwamoto M; Kobayashi T; Nishimura H; Yoshinaka R; Harada T; Tanigawa N
Oncol Rep; 2006 Apr; 15(4):803-8. PubMed ID: 16525662
[TBL] [Abstract][Full Text] [Related]
33. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.
Hu Y; Bandla S; Godfrey TE; Tan D; Luketich JD; Pennathur A; Qiu X; Hicks DG; Peters JH; Zhou Z
Mod Pathol; 2011 Jul; 24(7):899-907. PubMed ID: 21460800
[TBL] [Abstract][Full Text] [Related]
34. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.
Tubbs RR; Pettay JD; Roche PC; Stoler MH; Jenkins RB; Grogan TM
J Clin Oncol; 2001 May; 19(10):2714-21. PubMed ID: 11352964
[TBL] [Abstract][Full Text] [Related]
35. Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.
Ercolani C; Marchiò C; Di Benedetto A; Fabi A; Perracchio L; Vici P; Sperati F; Buglioni S; Arena V; Pescarmona E; Sapino A; Terrenato I; Mottolese M
J Exp Clin Cancer Res; 2017 Oct; 36(1):143. PubMed ID: 29029640
[TBL] [Abstract][Full Text] [Related]
36. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.
Hauser-Kronberger C; Dandachi N
J Mol Histol; 2004 Aug; 35(6):647-53. PubMed ID: 15614619
[TBL] [Abstract][Full Text] [Related]
37. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
[TBL] [Abstract][Full Text] [Related]
38. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
39. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
[TBL] [Abstract][Full Text] [Related]
40. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis.
Savage K; Lambros MB; Robertson D; Jones RL; Jones C; Mackay A; James M; Hornick JL; Pereira EM; Milanezi F; Fletcher CD; Schmitt FC; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2007 Jan; 13(1):90-101. PubMed ID: 17200343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
